Application of Botulinum Toxins in Non-spastic and Neurodegenerative Disorders
A special issue of Toxins (ISSN 2072-6651). This special issue belongs to the section "Bacterial Toxins".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 11491
Special Issue Editors
Interests: neuroplasticity; neurorehabilitation; spasticity; movement disorders; neurodegenerative diseases; botulinum toxin; facial nerve injuries; facial paresis; motion capture
Special Issue Information
Dear Colleagues,
In recent years, botulinum toxins (BoNT), beyond their massive use in conditions involving spastic muscle overactivity, have been used for the treatment of a large number of other medical indications, including the treatment of non-spastic motor and non-motor disorders. Many of the symptoms or syndromes for which BoNT has been found to be effective occur in a variety of neurological conditions, including neurodegenerative disorders. Botulinum toxins are highly potent biotoxins that can partially block nerve signals to muscles or other effectors. Suited doses make them potentially powerful therapeutic tools for excessive muscle contractions or autonomic dysfunctions.
This Special Issue will provide discussions on the application and development of botulinum toxins in the treatment of non-spastic motor and non-motor symptoms, particularly in the context of neurodegenerative diseases. Submissions can include reviews, systematic reviews, and meta-analyses, as well as original studies.
Dr. Marjolaine Baude
Prof. Dr. Jean-Michel Gracies
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- botulinum toxin
- non-spastic neurologic disorders
- neurodegenerative disorders
- parkinsonian syndromes
- idiopathic parkinson’s disease
- tremors
- facial paresis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.